Revista del Hospital Italiano de Buenos Aires (Sep 2023)
Surgical menopause in patients with BRCA mutation, the role of hormone therapy
Abstract
Introduction: Women with BRCA1/2 (mBRCA) mutation have an increased risk of developing breast (BC) and ovarian (OC) cancer. Bilateral salpingo-oophorectomy (BOS) is associated with an 80% risk reduction for OC and 50% for BC. The recommended age for this procedure is 35 to 40 years. The consequence is premature menopause, which hurts the quality of life due to the presence of climacteric symptoms, increased risk of cardiovascular disease, osteoporosis, and a higher risk of cognitive impairment. Hormone therapy (HTM) is the most effective treatment for preventing these symptoms. State of the art: Different studies have shown an increased risk of BC in postmenopausal women receiving HTM, particularly with combined therapy, estrogen + progesterone (E+P). According to the meta-analysis by Marchetti et al., in women carrying mBRCA who received HTM, there was no difference in the risk of BC compared to E alone with E+P. In the Kostopoulos study, there was also a possible protective effect in those who used E alone. Another study in healthy carriers showed that in women younger than 45 years at the time of BOS, HTM did not affect BC rates. However, in women older than 45 years, BC rates were higher. As the E+P scheme is associated with a higher RR of BC, the doses of progestogens should be limited, choosing natural progesterone byproducts of intermittent use to decrease systemic exposure. According to various international guidelines, healthy mBRCA carriers undergoing BOS should be offered HTM until the average age of menopause. Conclusion: premature menopause decreases life expectancy, which is why one of the tools to improve and prevent deterioration of quality of life is THM. Short-term use of MHT appears safe for women with mBRCA who undergo BOS before age 45 as it does not counteract the reduction in the risk of MC obtained by surgery.
Keywords
